After obtaining a degree in Medicinal Chemistry and Technology (2017, University of Milan, IT), Francesco Calzaferri completed a PhD in Pharmacology (2021, University Autónoma of Madrid, ES) under the supervision of Prof. Antonio G. Garcia and Cristóbal de los Ríos, funded by the ITN-Marie S. Curie "PurinesDX" programme. He conducted his postdoctoral research at the IBMM in Montpellier, where he was awarded a fellowship from the ARC Foundation, and subsequently in Prof. Silvia Giordani’s team (Dublin City University, IE). In 2026, he was recruited by the CNRS and rejoined the IBMM. Throughout his research career, he has worked in several international laboratories (IBEC in Barcelona, Ludwig Maximilians Universität in Munich, BSC UMR 7242 in Strasbourg, University of Eastern Finland in Kuopio, as well as Johnson & Johnson in Toledo). These experiences have consolidated his interdisciplinary profile at the interface of chemistry and biology, primarily focused on the discovery and optimisation of small ligands of therapeutic interest, such as P2X7 ion channel inhibitors for the treatment of neuroinflammation and pro-oxidant compounds as anticancer agents. Today, his research is oriented towards the development of innovative chemical probes targeting epigenetic mechanisms, specifically DNA and histone methylation, as a promising strategy in the fight against cancer.